STOCK TITAN

Damora Therapeutics (DMRA) Stock News

DMRA NASDAQ

Ticker history: GLTO became DMRA (Damora Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View GLTO history.

Damora Therapeutics, Inc. reports news around its biotechnology pipeline for mutCALR-driven blood disorders, financial results, and corporate development following the completed acquisition that added DMR-001, DMR-002, and DMR-003. Company updates also describe governance changes, board and executive appointments, and equity compensation actions under Nasdaq inducement-grant rules.

Recurring Damora news centers on hematologic disorders, myeloproliferative neoplasms, research and development progress, capital resources, and public-company governance matters tied to its Nasdaq-listed common stock.

Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) granted equity awards to five newly hired, non-executive employees on November 1, 2026, as employment inducements. The awards comprise options to purchase 120,900 ordinary shares at an exercise price of $21.49 per share, with a 10-year term.

The options vest 25% on the first anniversary of each employee’s start date, followed by equal monthly installments over 36 months. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4), subject to the 2022 Inducement Plan and option award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.42%
Tags
none
-
Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) reported a third-quarter 2026 net loss of $31.991 million while advancing its DMR-001 clinical trial. The loss widened from $3.133 million a year earlier. Research and development expenses rose to $25.475 million from $1.416 million, while general and administrative expenses increased to $11.388 million from $1.740 million.

Cash, cash equivalents and marketable securities totaled approximately $528.5 million at September 30, 2026; Damora expects funding to last into the second half of 2029. FDA clearance enables U.S. participation in CLARITY-101, whose dose-escalation enrollment is ongoing at multiple sites. Damora plans two clinical proof-of-concept datasets beginning mid-2027, with initial regulatory submissions for DMR-002 in the fourth quarter of 2026 and DMR-003 in 2027. It also secured an exclusive worldwide, royalty-bearing license from Paragon Therapeutics for DMR-001 and DMR-002.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
-
Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) announced new preclinical DMR-001 results showing an average 95-fold improvement in anti-proliferative potency versus a reference antibody.

The head-to-head studies tested a panel of 10 non-Type 1 CALR mutations, including Type 2, and measured inhibition of cell proliferation. The findings extend previously presented activity against Type 1 and Type 2 mutations. A poster will present the data at the ASH Annual Meeting on December 12, 2026.

DMR-001 is being evaluated in the ongoing CLARITY-101 Phase 1/1b trial for mutant CALR-driven essential thrombocythemia and myelofibrosis, both blood disorders. A separate trial-in-progress poster on December 13 will describe its dose-escalation design. Damora expects the design to expedite selection of a recommended dose for planned Phase 1b expansion cohorts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags
none
Rhea-AI Summary

Damora Therapeutics (DMRA) granted equity awards to five newly hired, non-executive employees on October 1, 2026, as inducements to accept employment.

The awards comprise options to purchase 144,400 ordinary shares at an exercise price of $21.28 per share, with a 10-year term. Options vest 25% on the first anniversary of each employee’s start date, then in equal monthly installments over the following 36 months. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4). The awards are subject to the 2022 Damora Therapeutics Inducement Plan and an option award agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
Rhea-AI Summary

Damora Therapeutics (DMRA) granted equity inducement awards to three newly hired non-executive employees on September 1, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the company’s independent Compensation Committee as material inducements to the employees’ acceptance of employment.

The inducement grants consist of options to purchase an aggregate of 135,400 ordinary shares, each with a 10-year term and an exercise price of $28.18 per share. All options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in equal monthly installments over the following 36 months. The options are granted pursuant to the company’s 2022 Inducement Plan and individual option award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) reported second quarter 2026 results highlighted by initiation of the global Phase 1/1b CLARITY-101 trial of lead candidate DMR-001 in mutant calreticulin (mutCALR)-driven essential thrombocythemia and myelofibrosis, following health authority approvals.

The company also presented DMR-001 preclinical data at EHA 2026 showing up to 30-fold higher binding affinity, 26-fold greater inhibition of cellular proliferation in Type 2 mutCALR, and a five-fold longer half-life versus a reference antibody, supporting predicted once-monthly subcutaneous dosing. Biotech executive Dr. Andrew Cheng joined the board.

Cash and cash equivalents were $540.5 million as of June 30, 2026, which Damora Therapeutics expects to fund operations into the second half of 2029. Second quarter R&D expenses were $25.5 million and G&A $9.5 million, leading to a net loss of $31.2 million, compared with $3.4 million a year earlier. Upcoming milestones include first regulatory submissions for DMR-002 in the second half of 2026 and DMR-003 in 2027, and two clinical proof-of-concept datasets for DMR-001 beginning mid-2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) has initiated the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational monoclonal antibody targeting mutant calreticulin (mutCALR), in adults with mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF), following health authority approvals.

The open-label, multi-center dose-escalation and expansion study will evaluate safety, tolerability and preliminary efficacy, starting at a predicted-therapeutic dose of 100 mg once monthly by subcutaneous injection, using an adaptive Bayesian design for cohort enrichment. Eligible patients have documented CALR mutations and ET or MF resistant, refractory or intolerant to prior standard therapies, with expansion planned into earlier-line and combination settings.

DMR-001 is engineered to selectively block mutCALR–thrombopoietin receptor interactions while sparing wild-type calreticulin, with Fc-null and YTE half-life–extending modifications. According to Damora Therapeutics, preclinical data showed up to 30-fold higher mutCALR binding affinity and about five-fold longer half-life than a reference antibody, supporting once-monthly dosing. Initial clinical data are expected beginning mid-2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.70%
Tags
-
Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to six newly hired non-executive employees on August 1, 2026. The independent Compensation Committee approved these grants as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).

The awards comprise stock options to purchase an aggregate of 451,000 ordinary shares, with a 10-year term and an exercise price of $28.99 per share. Each option vests 25% on the first anniversary of the employee’s start date and then in equal monthly installments over the following 36 months. The options are granted under the 2022 Damora Therapeutics Inducement Plan and are subject to the plan and related option award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Summary

Damora (NASDAQ: DMRA) completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026. Each Delaware common share converted into one Cayman ordinary share, and each preferred share converted into the corresponding Cayman series. Nasdaq trading will continue under “DMRA” with a new CUSIP, G2646Y104, effective July 20, 2026. According to Damora, the move does not change its business, management, obligations, assets, or liabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.10%
Tags
none
Rhea-AI Summary

Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to nine newly hired, non-executive employees on July 1, 2026. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), are non-qualified stock options for an aggregate 453,500 shares at a $26.01 exercise price.

The options have a 10-year term and vest 25% on the first anniversary of each employee’s start date, then in equal monthly installments over the following 36 months, under the 2022 Damora Therapeutics Inducement Plan and related award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.67%
Tags
none

FAQ

What is the current stock price of Damora Therapeutics (DMRA)?

Damora Therapeutics (DMRA) last closed at $22.50.

What is the market cap of Damora Therapeutics (DMRA)?

The market cap of Damora Therapeutics (DMRA) is approximately $1.4B.